Dr. Reddy's Laboratories

We are committed to developing affordable and innovative pharmaceuticals by investing in cutting-edge science and technology, nurturing talented scientists, and fostering an environment that encourages innovation across all aspects of product development. In this episode of #ScientistInSpotlight, we hear from Dr. Subramanian Narayanaswamy, Head of Delivery, Parenteral Injectables – IPDO, as he shares his journey into the world of science and his professional trajectory. He highlights the significance of peptides- Semaglutide and Liraglutide, and discusses our market presence in the treatment of diabetes and obesity. From the very beginning, our strategy and execution have been bold, venturing into new frontiers of science and technology. Our pioneering spirit and relentless pursuit of excellence have led us to achieve numerous industry firsts. Our #ScientistInSpotlight series aims to capture this spirit of bold vision and our deep commitment to science, as expressed through the voices of our scientists. In this series, they share their journeys, insights, and the scientific challenges that continue to inspire them. Click here to watch the full video: https://lnkd.in/d8s2bB3r #SIS #Peptides #GoodHealthCantWait #WeAreDrReddys

Just 10 days to go for #ASCO25, the American Society of Clinical Oncology! Our Emerging Markets (EM) oncology team will be present at the conference, held from May 30th to June 3rd in Chicago, Illinois. The event will feature the latest cutting-edge data, provide high-quality education, and offer networking opportunities for oncologists and other stakeholders from around the world. Last year, the conference was attended by over 45,000 oncologists, industry professionals, and patient advocacy activists. Visit our booths #15123 and #16154 at ASCO 2025 in Chicago, Illinois. Stay tuned for more updates. #ASCO25 #Oncology #DrReddysAtASCO #GoodHealthCantWait #WeAreDrReddys

On the first week of April, we welcomed interns from our Summer Internship Program FY26. These interns earned their place through the Destination Dr. Reddy’s case study competition organised by our early careers team. From exploring innovative assets for international markets to optimising cold chain logistics, our interns are tackling diverse and impactful projects. Their journey began with a two-day induction designed to ease their transition from campus to industry. We look forward to seeing the innovative solutions they bring to the table. A warm welcome to our interns, we are happy to to have you on this journey with us! #SummerInternshipProgram #DestinationDrReddys #WeAreDrReddys #GoodHealthCantWait

My granddaughter reminded me to buy a tooth paste this evening and I ordered a brand that I launched 20 years ago. A story to share with my granddaughter to her delight …. Cheerio , the specifically formulated tooth paste for kids from DRL. I recalled the year 2005, when there were no tooth paste products for children. As a Head of Recura division in DRL, I saw this segmentation opportunity for a tooth paste. The division managed portfolios for Gastro , Derma and Dental specialists. R&D team of DRL was enthusiastic about developing a formulation meeting the expectations of a Child. Coining an appropriate brand name “Cheerio”, ( every home with kids is used to hear the word Cheerio ) developing a pack that kids would love to open every morning ( the tooth paste cap was fitted with a rooster ) … coining a phrase “My paste-My taste” for the pack (my grand daughter brought the meaning to this line's objective on the pack. She read it with her nursery language skill and felt proud with a smile) … every aspect is fresh in my memory and I shared the story to my granddaughter. I am curious to know the sales value of Cheerio today…. The packaging has remained the same since it’s launch in 2006. Any DRL marketing colleague can share the value reported in iqvia, please. Dr. Reddy's Laboratories

#HappyMothersDay to all the incredible mothers out there! Motherhood is a journey filled with countless challenges and opportunities. We take pride in our employees who are mothers, displaying remarkable fortitude as they balance their careers and young ones. At Dr. Reddy's, we believe that no woman should have to choose between her career and raising a family. Earlier last year, we announced the pilot of our ‘Womb to the World’ initiative in of our women employees who are full-time working mothers. We are proud to share that this initiative has been extended to all women colleagues in India. W.O.W is designed to our working mothers from pre-natal care to early childcare and beyond. W.O.W represents several elements – an effort to help women remain in the professional workforce, working parents, and make a generational investment in the relationships and well-being of our employees and their children. This initiative has benefitted many of our working mothers, helping them find their strength and through W.O.W. Our diversity, equity, and inclusion journey is a work in progress, and we have a long way to go, but we are committed to representing the diversity of the society within which we live. Together, let's continue to champion diversity, equity, and inclusion in the workplace and beyond. Happy Mother's Day! To learn more about our ESG goals, please visit: http://bit.ly/3ZMMWRM #HappyMothersDay #WeAreDrReddys #GoodHealthCantWait #WOW

Our Emerging Markets (EM) oncology team will be participating in ASCO 2025 (American Society of Clinical Oncology). The 2025 ASCO Annual Meeting is a global gathering where oncology professionals connect and collaborate. The event gathers oncologists, industry professionals and patient advocacy activists to shape the future of cancer care. We look forward to using this opportunity to interact with the oncology-care community, to showcase our capabilities, and to explore what we can do for patients and partners in oncology. Visit our booths #15123 and #16154 to take this conversation forward. #ASCO25 #Oncology #DrReddysXASCO #GoodHealthCantWait #WeAreDrReddys

Today we announced our Q4 FY'25 financial results. For more details click here: https://shorturl.at/gf6GT #Q4FY25FinancialResults #WeAreDrReddys #GoodHealthCantWait

Today, we expanded our partnership with Sanofi Healthcare India Private Limited (SHIPL) to launch Beyfortus®️ (nirsevimab), a novel drug for preventing Respiratory Syncytial Virus (RSV) in India. RSV is a highly contagious virus that can lead to serious respiratory illness in infants. With this partnership, we will have exclusive rights from SHIPL to promote and distribute Beyfortus®️ (nirsevimab) in India. Beyfortus®️ is expected to be launched in India in the second quarter of the current fiscal year. Our Chief Executive Officer, Branded Markets (India and Emerging Markets), M.V. Ramana, said, “We are happy to extend our partnership with Sanofi in India - this time for a novel drug to address the RSV burden among newborns and infants in India. This partnership highlights our continued efforts to become the ‘partner of choice’ in bringing novel, innovative, and trusted drugs to patients. Beyfortus®️ enables healthcare professionals and parents to access an improved drug for the prevention of RSV. Additionally, the launch of Beyfortus®️ will help us strengthen our immunization portfolio in India.” With each product, we continue our endeavor to drive access and affordability of innovative products, and our journey towards serving over 1.5 billion patients by 2030. Click here to read more: https://lnkd.in/dhgmt6iu #RSV #ProductLaunch #WorldImmunizationWeek #GoodHealthCantWait #WeAreDrReddys

Heading to #AXS25 in Las Vegas? Connect with us this year to see what’s new from our team and experience the change that working together can bring. See you there! Visit us at Booth 1414. #pharmaceuticals #WeAreDrReddys #GoodHealthCantWait #TogetherinHealth #Biologics #Healthcare

“If we define the problem right, India has the knack to solve it.” At #nasscomGCC Summit & Awards 2025, Rajesh Nambiar - President, Nasscom, and Prasad G V - Co-Chairman & MD, Dr. Reddy's Laboratories, explored how AI is reshaping drug discovery. - With modeling, GPUs, and fundamental science, AI is accelerating biology by enabling breakthroughs without proportionate effort. It’s not just ; it’s a force multiplier redefining what’s curable. - While innovation companies focus on developing novel therapies, generic companies play a critical role in making those therapies affordable – a duality that ensures healthcare remains both advanced and accessible. - Regulation, rooted in “do no harm,” isn’t a hurdle but a part of the process, with surveillance ensuring health safety without stalling innovation. #nasscomGCC #DrugDiscovery #AIinHealthcare #InnovationAndAccess #FutureOfHealth